BMC Psychiatry

Table 3 Patients’ functioning at baseline (T0), at 9 months (T1) and at 18 months follow-ups (T2) (A) and paired differences for functioning at baseline (GAFT0), at 9 months (GAFT1) and at 18 months follow-ups (GAFT2) (B) by diagnostic groups

From: Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS)

	FEP^a			CHR-P^b			CHR-N^c			ALL			p1
	T0	T1	T2	T0	T1	T2	T0	T1	T2	T0	T1	T2	T0	T1	T2
	n = 130	n = 130	n = 129	n = 60	n = 59	n = 59	n = 47	n = 47	n = 47	n = 237	n = 236	n = 235
A
GAF (%)
Good (61–100)	15.4	37.7	43.4	18.3	32.2	44.1	25.5	42.6	48.9	18.1	37.3	44.7	< 0.001	0.053	0.053
Moderate (41–60)	46.2	33.8	29.5	66.7	54.2	45.8	70.2	38.3	34.0	56.1	39.8	34.5
Poor (0–40)	38.5	28.5	27.1	15.0	13.6	10.2	4.3	19.1	17.0	25.7	22.9	20.9
Mean	48.0	57.1	59.3	53.7	56.6	62.2	58.2	59.4	61.6	51.4	57.4	60.5	< 0.001	0.679	0.548
SD	14.4	18.7	19.7	10.8	15.1	17.2	9.1	16.2	17.4	13.2	17.3	18.6
B
	Mean	SD		t	p
FEP^a (df = 128–129)
GAFT0 - GAFT1	−9.18	17.75		−5.90	< 0.001
GAFT0 - GAFT2	−11.48	18.95		−6.88	< 0.001
GAFT1 - GAFT2	−2.31	14.00		−1.87	0.063
CHR-P^b (df = 58)
GAFT0 - GAFT1	−2.31	13.61		−1.30	0.198
GAFT0 - GAFT2	−7.88	17.84		−3.39	0.001
GAFT1 - GAFT2	−5.58	15.07		−2.84	0.006
CHR-N^c (df = 46)
GAFT0 - GAFT1	−1.23	16.86		−0.50	0.618
GAFT0 - GAFT2	−3.47	16.43		−1.45	0.155
GAFT1 - GAFT2	−2.23	8.31		−1.84	0.072
ALL (df = 234–235)
GAFT0 - GAFT1	−5.88	16.96		−5.32	< 0.001
GAFT0 - GAFT2	−8.97	18.39		−7.48	< 0.001
GAFT1 - GAFT2	−3.11	13.38		−3.57	< 0.001

^aFirst-episode psychosis
^bConfirmed clinical high-risk to psychosis
^cNonconfirmed clinical high risk to psychosis. p1 = significance between FEP, CHR-P and CHR-N

Back to article page

ISSN: 1471-244X

Contact us

Submission enquiries: bmcpsychiatry@biomedcentral.com
General enquiries: ORSupport@springernature.com